Table 2.
- Comparison between Group 1 and Group (N=73).
| Characteristics | Group 1 | Group 2 | P-value |
|---|---|---|---|
| Ratio <0.32 | Ratio ≥0.32 | ||
| (n=44) | (n=29) | ||
| Gender | |||
| Male | 34 (77.3) | 22 (75.9) | 0.889 |
| Female | 10 (22.7) | 7 (24.1) | |
| Age | 66.57±12.31 (67.50) | 66.38 ± 11.06 (67) | 0.947 |
| Presence of comorbidities | |||
| No | 24 (54.5) | 16 (55.2) | 0.669 |
| yes | 20((45.5) | 13(44.8) | |
| Operation width | |||
| Subtotal gastrectomy + D2 LN Dissection | 26 (59.1) | 16 (55.2) | 0.74 |
| Total gastrectomy + D2 Lymph node dissection | 18 (40.9) | 12 (44.8) | |
| Cholecystectomy | 5 (11.4) | 3 (10.3) | 0.892 |
| Splenectomy | 3 (6.8) | 1 (3.4) | 0.536 |
| Hospitalization period (days) | 10.68±5.91 (9) | 9.24±1.92 (9) | 0.485 |
| Chemotherapy | 36 (81.8%) | 26 (89.7) | 0.36 |
| TLN | 18.77±9.36 (19) | 25.10±13.64 (24) | 0.04 |
| MLN | 2.14±2.51 (1) | 15.97±10.30 (13) | <0.001 |
| Follow-up | 22.84±15.47 (22.5) | 14.14±15.19 (8) | 0.009 |
| Mortality | 8 (18.2) | 15 (51.7) | 0.003 |
| Average estimated survival time (months) | 48.01 | 24.22 | 0.001 |
Values are presented as number and percentages (%). TLN: total number of lymph nodes, MLN: number of metastatic lymph nodes